(Q33394981)

English

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

5

object named as

Xavier Leleu

0 references

Philippe Moreau

1

object named as

Philippe Moreau

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sebastian Grosicki

3

object named as

Sebastian Grosicki

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Halyna Pylypenko

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ievgenii Karamanesht

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maria Grishunina

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Grigoriy Rekhtman

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Zvenyslava Masliak

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anna Shubina

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bertrand Arnulf

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Kropff

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James Cavet

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dixie-Lee Esseltine

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Huaibao Feng

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Suzette Girgis

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Helgi van de Velde

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

William Deraedt

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jean-Luc Harousseau

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

18 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

431-440

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970081-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70081-X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33394981&oldid=1536424423"